{"product_id":"scyx-vrio-analysis","title":"SCYNEXIS, Inc. (SCYX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDive into the VRIO analysis of SCYNEXIS, Inc. (SCYX) to uncover the true source of its competitive edge. Is its current success built on fleeting advantages or truly inimitable assets? This distilled summary reveals whether SCYNEXIS, Inc. (SCYX) possesses the Value, Rarity, Inimitability, and Organization needed for sustained dominance - read on to find out!\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSCYNEXIS, Inc. (SCYX) - VRIO Analysis: \u003cstrong\u003eProprietary Triterpenoid Antifungal Platform (Fungerps)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou are looking at the core engine of SCYNEXIS, the Fungerps platform, which is what makes their assets like ibrexafungerp and the newer SCY-247 potentially game-changing in the antifungal space. The value here isn't abstract; it’s tied directly to overcoming resistance, a major public health crisis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Novel Mechanism Against Resistance\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe platform’s value stems from its novel mechanism of action as a glucan synthase inhibitor, which is key to fighting resistant strains. This is critical because the World Health Organization has called for action in this area due to rising resistance. The pipeline is built on this foundation, with the second-generation candidate, SCY-247, showing positive Phase 1 results as of September 2025, achieving target exposures at lower doses than the first-generation drug.\u003c\/p\u003e\n\u003cp\u003eThe company is actively investing in this future, reporting R\u0026amp;D expenses of \u003cstrong\u003e$5.5 million\u003c\/strong\u003e for the three months ended September 30, 2025. Plus, the platform's potential is being recognized externally, with a federal grant announced in November 2025 to fund further development of novel fungerps.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Unique Chemical Class\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe triterpenoid chemical class is rare in the current antifungal market. This uniqueness is what allows SCY-247 to show potent activity against multidrug- and pandrug-resistant pathogens like C. auris and Aspergillus species. Honestly, having a distinct chemical structure in a market dominated by older classes is a massive advantage.\u003c\/p\u003e\n\u003cp\u003eIt’s a true differentiator. \u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High Barrier to Entry\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReplicating this platform would require significant, specialized research and discovery investment over many years, making it highly inimitable in the near term. The years of work that led to both ibrexafungerp and SCY-247 create a time-based barrier. What this estimate hides is the specific institutional knowledge required to synthesize and optimize these compounds effectively.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Focused Execution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSCYNEXIS is clearly organized around exploiting this platform. They are moving SCY-247 toward a planned Phase 2 study in invasive candidiasis, with proof-of-concept data expected in 2026. Furthermore, the recent financial restructuring, including a $24.8 million one-time payment from GSK expected in Q4 2025, provides a cash runway of more than two years to support this development. The company is also actively exploring non-dilutive funding to keep this momentum going.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained Potential\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBecause the platform is both valuable and rare, and difficult to copy, it forms the basis for a sustained competitive advantage, provided they can successfully bring SCY-247 to market with both oral and IV formulations. The existing product, ibrexafungerp, licensed to GSK, still carries potential upside of up to approximately $146 million in annual net sales milestones plus royalties.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick view of the platform and pipeline status as of late 2025:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eKey Supporting Data \/ Pipeline Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eNovel mechanism against resistant fungi; SCY-247 Phase 1 positive data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eUnique triterpenoid chemical class.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eRequires years of specialized discovery investment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eFocused on SCY-247 Phase 2 initiation; cash runway \u0026gt; 2 years post-GSK payment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained Potential\u003c\/td\u003e\n\u003ctd\u003eFoundation for differentiated offerings like SCY-247 (oral\/IV).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eYou should track the initiation of the SCY-247 Phase 2 study closely, as that will be the next major inflection point for platform validation beyond Phase 1. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSCYNEXIS, Inc. (SCYX) - VRIO Analysis: \u003cstrong\u003eIbrexafungerp (Approved Product Status)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below focuses on Ibrexafungerp's status as an approved product, leveraging publicly available financial and operational data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe asset provides a validated, approved product with two existing indications: vulvovaginal candidiasis (VVC) approved in June 2021, and reduction in the incidence of recurrent VVC approved in November 2022. The asset is currently generating license revenue associated with the GSK License Agreement. For the three months ended September 30, 2025, this revenue was reported as \u003cstrong\u003e\\$0.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA Approval for VVC: June 2021.\u003c\/li\u003e\n\u003cli\u003eFDA Approval for Recurrent VVC: November 2022.\u003c\/li\u003e\n\u003cli\u003eLicense Agreement Revenue (Q3 2025): \u003cstrong\u003e\\$0.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; while other oral antifungals exist, Ibrexafungerp represents the first of the novel triterpenoid antifungal class ('fungerps') to obtain regulatory approval, suggesting a relatively new mechanism to the market.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow for the approved drug substance itself due to patent protection, but the market position is vulnerable if the planned relaunch stalls. The potential financial upside is tied to future performance metrics post-relaunch.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNDA Transfer Completion Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Annual Net Sales Milestones (Post-Relaunch)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e\\$145.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Rate (Post-Relaunch)\u003c\/td\u003e\n\u003ctd\u003eLow to mid-single-digit range (net of payments to Merck)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments (End of Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$37.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOne-Time Payment from GSK (Expected Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$24.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is actively executing on the transfer of the New Drug Application (NDA) for BREXAFEMME to GSK, which was completed on \u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e. This action is intended to position the asset for a controlled relaunch under GSK's management, extending the company's cash runway to more than \u003cstrong\u003etwo years\u003c\/strong\u003e following an expected Q4 2025 payment from GSK.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNDA Transfer Status: \u003cstrong\u003eCompleted\u003c\/strong\u003e as of November 19, 2025.\u003c\/li\u003e\n\u003cli\u003eGSK Anticipated Regulatory Interactions: Beginning in 2026.\u003c\/li\u003e\n\u003cli\u003eCash Runway Extension: Greater than \u003cstrong\u003etwo years\u003c\/strong\u003e post-Q4 2025 GSK payment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe competitive advantage is currently considered \u003cstrong\u003eTemporary\u003c\/strong\u003e, contingent upon the successful relaunch by GSK and subsequent market penetration against established therapies. The primary financial realization of this advantage is through future performance-based milestones and royalties.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSCYNEXIS, Inc. (SCYX) - VRIO Analysis: \u003cstrong\u003eSCY-247 Second-Generation Fungerp Candidate\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eSCY-247 represents a potential superior product with positive Phase 1 SAD\/MAD data showing good tolerability and efficacy at lower doses than the first generation. The Phase 1 study involved 88 healthy participants. Orally administered SCY-247 achieved target exposures at doses lower than the first-generation fungerp. The study evaluated Single Ascending Doses (SAD) ranging from 50mg to 900mg and Multiple Ascending Doses (MAD) ranging from 50mg to 300mg once daily for seven days.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe drug demonstrated good tolerability across all assessed cohorts, with no reports of serious or severe treatment-emergent adverse events. The most common adverse events were mild to moderate headache, reported in 16.7% of participants receiving SCY-247 versus 4.5% receiving placebo, and diarrhea reported in 9% of participants in both the treatment and placebo groups. Multiple ascending dose cohorts of 200mg and 300mg once-daily achieved or exceeded the preliminary target for efficacious exposure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; a well-tolerated, second-generation asset showing promise in Phase 1 is rare for a company of this size, which had a market capitalization of approximately $27.57 Million USD as of December 2025. The company has 28 employees.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; requires replicating the entire specialized discovery and development pathway. The company's strong liquidity position is reflected in its healthy current ratio of 5.2. The company's Fiscal Year Net Income was $-21.29 M USD.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes, management is prioritizing its advancement, planning a Phase 2 study with proof-of-concept data expected in 2026. Wall Street analysts forecast SCYX stock price to have a 1-year average target of $3.50 USD, with a range between $3.00 USD and $4.00 USD.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained, if it successfully navigates clinical trials and secures a strong market position. SCY-247 is part of the fungerp family, the first new class of antifungal compounds since 2001.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key Phase 1 data points for SCY-247:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eParameter\u003c\/th\u003e\n\u003cth\u003eSCY-247 Value\u003c\/th\u003e\n\u003cth\u003eComparison\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAD Dose Range\u003c\/td\u003e\n\u003ctd\u003e50mg to 900mg\u003c\/td\u003e\n\u003ctd\u003eEvaluated in Phase 1 study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAD Dose Range\u003c\/td\u003e\n\u003ctd\u003e50mg to 300mg\u003c\/td\u003e\n\u003ctd\u003eAdministered once daily for 7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficacious Exposure Achieved\u003c\/td\u003e\n\u003ctd\u003e200mg and 300mg MAD cohorts\u003c\/td\u003e\n\u003ctd\u003eAchieved or exceeded preliminary target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak Concentration Time (Tmax)\u003c\/td\u003e\n\u003ctd\u003e3 to 7 hours\u003c\/td\u003e\n\u003ctd\u003eRapid absorption observed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSerious\/Severe TEAEs\u003c\/td\u003e\n\u003ctd\u003eZero\u003c\/td\u003e\n\u003ctd\u003eAcross all evaluated cohorts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's organizational structure and financial health provide a foundation for continued development:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMarket Capitalization: Approximately $27.7 million as of December 2025.\u003c\/li\u003e\n\u003cli\u003eCurrent Ratio: 5.2.\u003c\/li\u003e\n\u003cli\u003eEmployees: 28.\u003c\/li\u003e\n\u003cli\u003eFY Revenue: $3.75 M USD.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSCYNEXIS, Inc. (SCYX) - VRIO Analysis: \u003cstrong\u003eGSK License Agreement \u0026amp; Future Revenue Streams\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eFuture cash flow potential is anchored by the exclusive license agreement with GSK for BREXAFEMME (ibrexafungerp tablets). SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones post-relaunch, in addition to royalties payable in the low-to-mid single-digit percentage range, net of payments due to Merck. The company has already received a $90 million upfront payment and achieved $25 million in a development milestone, totaling $115 million in upfront and milestone payments as of June 2023. A recent amendment resulted in an additional $24.3 million payment related to the termination of the MARIO study ($22 million plus $2.3 million for wind-down activities).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Component\u003c\/th\u003e\n\u003cth\u003eOriginal Potential (Max)\u003c\/th\u003e\n\u003cth\u003eStatus\/Latest Figure\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$90 million\u003c\/strong\u003e received\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment Milestones (Total)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$75.5 million\u003c\/strong\u003e (incl. MARIO)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$25 million\u003c\/strong\u003e achieved; MARIO-related milestones resolved with \u003cstrong\u003e$24.3 million\u003c\/strong\u003e payment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Milestones (IC Indication)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$70 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUnspecified status post-amendment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Milestones (IC Sale)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$115 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUnspecified status post-amendment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales Milestones (Annual Net Sales)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$242.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReplaced by post-relaunch annual milestones up to \u003cstrong\u003e$145.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestones (Original)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$503 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-relaunch annual milestones up to \u003cstrong\u003e$145.5 million\u003c\/strong\u003e plus royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eMid-single digit to mid-teen digit\u003c\/strong\u003e tiered percentages\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eLow-to-mid single-digit\u003c\/strong\u003e percentage range (post-relaunch)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; large pharmaceutical partnerships are routine, but the specific structure involving the transfer of an already approved NDA for a novel antifungal class (fungerps) and the associated tiered royalty\/milestone cascade is specific to SCYNEXIS, Inc. The initial agreement granted GSK exclusive rights outside Greater China and certain other licensed countries.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow; the specific contract terms, including the defined milestone payments, royalty structure, and the recent resolution regarding the MARIO study, are unique to the negotiated agreement and cannot be directly copied by competitors.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes, the company is actively managing the asset transfer to trigger future payments. The transfer of the BREXAFEMME New Drug Application (NDA) to GSK was completed on November 19, 2025. GSK anticipates initiating regulatory interactions with the U.S. Food and Drug Administration (FDA) in 2026 to discuss a U.S. relaunch for vulvovaginal candidiasis (VVC) and refractory VVC (rVVC).\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; the advantage is derived from the existing, in-place commercial partnership with GSK, which provides a significant, non-dilutive capital source contingent on GSK's commercial success and regulatory progress. The company retains rights to other assets derived from the novel “fungerp” antifungal class, including SCY-247.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBREXAFEMME is the only oral drug green-lighted by U.S. regulators for VVC and rVVC.\u003c\/li\u003e\n\u003cli\u003eThe original agreement was dated March 30, 2023.\u003c\/li\u003e\n\u003cli\u003eThe company's market capitalization was reported at $34 million as of October 15, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSCYNEXIS, Inc. (SCYX) - VRIO Analysis: \u003cstrong\u003eStrong Near-Term Liquidity Position\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: Value: Provides operational stability, allowing focused development of SCY-247 without immediate dilution concerns.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: Rarity: High for a clinical-stage biotech;\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Status\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents and Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$37.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eZero\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAfter repaying convertible notes in March 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGSK One-Time Payment (Expected)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nImitability: Imitability: Low; this specific cash buffer is the result of past financing and the recent \u003cstrong\u003e$24.8 million\u003c\/strong\u003e GSK settlement.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: Organization: Yes, management is leveraging this stability to fund R\u0026amp;D and explore non-dilutive funding for SCY-247.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement is exploring \u003cstrong\u003enon-dilutive funding\u003c\/strong\u003e opportunities to support SCY-247 development.\u003c\/li\u003e\n\u003cli\u003eNet cash used in financing activities for the nine months ended September 30, 2025, consisted primarily of the \u003cstrong\u003e$14.0 million\u003c\/strong\u003e repayment of convertible debt in March 2025.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the three months ended September 30, 2025, were \u003cstrong\u003e$5.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nCompetitive Advantage: Competitive Advantage: Temporary, as cash reserves will be drawn down over the projected runway exceeding \u003cstrong\u003etwo years\u003c\/strong\u003e post-GSK payment.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSCYNEXIS, Inc. (SCYX) - VRIO Analysis: \u003cstrong\u003eRegulatory Designations for Ibrexafungerp\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Regulatory designations provide market exclusivity incentives and potential development timeline acceleration for specific indications.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDesignation Type\u003c\/th\u003e\n\u003cth\u003eIndication\/Status\u003c\/th\u003e\n\u003cth\u003eRegulatory Body\u003c\/th\u003e\n\u003cth\u003eExclusivity\/Protection Duration\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQIDP\/Fast Track\u003c\/td\u003e\n\u003ctd\u003eVulvovaginal Candidiasis (VVC) and Recurrent VVC (RVVC)\u003c\/td\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003eExpected 10 years U.S. market exclusivity (NCE + QIDP extension)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan Drug Designation\u003c\/td\u003e\n\u003ctd\u003eInvasive Candidiasis (IC)\u003c\/td\u003e\n\u003ctd\u003eEMA\u003c\/td\u003e\n\u003ctd\u003e10 years EU market exclusivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan Drug Designation\u003c\/td\u003e\n\u003ctd\u003eInvasive Candidiasis (IC) and Invasive Aspergillosis (IA)\u003c\/td\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003eN\/A for duration, but supports development for high-need areas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Protection\u003c\/td\u003e\n\u003ctd\u003eComposition-of-Matter\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eExpected expiration in 2035\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; designations are based on scientific merit for specific, high-need indications.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA approval for VVC: June 1, 2021.\u003c\/li\u003e\n\u003cli\u003eFDA approval for RVVC: November 30, 2022.\u003c\/li\u003e\n\u003cli\u003ePotential market size for IC indication: Approximately 35,000 cases of azole-resistant IC annually in the U.S..\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; granted by the FDA\/EMA based on scientific assessment of unmet need, not easily replicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes; designations directly inform and streamline regulatory strategy for lead product lifecycle management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained for the duration of exclusivity periods granted for specific uses.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal potential U.S. protection period combining exclusivity and patent term extension estimated at almost 15 years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSCYNEXIS, Inc. (SCYX) - VRIO Analysis: \u003cstrong\u003eCore Scientific Expertise in Antifungal Resistance\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe core scientific expertise centers on the proprietary triterpenoid class of antifungals, known as 'fungerps,' which represent the first new class of antifungal compounds approved since \u003cstrong\u003e2001\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eDeep, specialized knowledge focused on combating difficult-to-treat and drug-resistant infections, a growing global health crisis. The global antifungal drugs market size was valued at \u003cstrong\u003eUSD 16.38 billion\u003c\/strong\u003e in 2024 and is anticipated to reach nearly \u003cstrong\u003eUSD 24.25 billion\u003c\/strong\u003e by 2034. The expertise addresses pathogens like Candida auris, where cases doubled from \u003cstrong\u003e756 in 2020\u003c\/strong\u003e to \u003cstrong\u003e1,471 in 2021\u003c\/strong\u003e, carrying a high mortality rate of \u003cstrong\u003e30%-60%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerate; while other firms target infections, this deep specialization in overcoming resistance is less common. The company’s first-generation compound, ibrexafungerp, is the first antifungal in what is only the fourth antifungal class to reach the market. The company secured approximately \u003cstrong\u003e$7 million\u003c\/strong\u003e annually via a five-year federal grant from NIAID to develop new therapeutics for resistant fungal infections.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerate; requires years of accumulated institutional knowledge and specialized scientific talent. Research and development expense for the full year ended December 31, 2024, was \u003cstrong\u003e$26.4 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$30.9 million\u003c\/strong\u003e for the same period in 2023. The company received a \u003cstrong\u003e$10 million\u003c\/strong\u003e development milestone payment from GSK in Q3 2024 for completing trials in refractory or resistant invasive fungal infections.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eYes, the entire corporate mission and R\u0026amp;D focus are aligned with this high-need niche. The company ended Q3 2024 with cash, cash equivalents, and investments totaling \u003cstrong\u003e$84.9 million\u003c\/strong\u003e, projecting a cash runway into \u003cstrong\u003eQ3 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eSustained, as long as the company maintains its scientific lead in this specialized area. The second-generation candidate, SCY-247, is on track for Phase 1 initiation in \u003cstrong\u003eQ4 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Period\u003c\/td\u003e\n\u003ctd\u003eContext\/Product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (Sep 30, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$84.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash, cash equivalents, and investments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ3 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on current operating plan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestone Payment Received\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 from GSK for refractory infection trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $30.9 million in FY 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePipeline Status and Key Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIbrexafungerp (BREXAFEMME®) received its second U.S. indication in \u003cstrong\u003eNovember 2022\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSCY-247 Phase 1 study evaluated SAD doses up to \u003cstrong\u003e900mg\u003c\/strong\u003e and MAD doses up to \u003cstrong\u003e300mg\u003c\/strong\u003e once-daily.\u003c\/li\u003e\n\u003cli\u003eThe company is advancing SCY-247 to address invasive fungal infections, including strains like Candida auris and echinocandin-resistant Candida glabrata.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSCYNEXIS, Inc. (SCYX) - VRIO Analysis: \u003cstrong\u003eNDA Transfer Execution Capability\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe operational ability to successfully transfer the BREXAFEMME New Drug Application (NDA) to GSK by year-end 2025, which is crucial for unlocking the royalty\/milestone stream.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNDA Transfer Completion Date\u003c\/td\u003e\n\u003ctd\u003eCompleted\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Annual Net Sales Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$145.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUpon Relaunch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eLow to mid single digit range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOn Net Sales Post-Relaunch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected GSK Regulatory Interaction Start\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-NDA Transfer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway (as of Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ4 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFrom \u003cstrong\u003e$46.5 million\u003c\/strong\u003e cash balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-NDA Related GSK Payment Received\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$22 million\u003c\/strong\u003e + \u003cstrong\u003e$2.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eResolution of MARIO Study Disagreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\nThe operational ability to successfully transfer the BREXAFEMME New Drug Application (NDA) to GSK by year-end 2025, which is crucial for unlocking the royalty\/milestone stream, representing potential future non-dilutive capital of up to \u003cstrong\u003e$145.5 million\u003c\/strong\u003e in annual net sales milestones plus royalties in the \u003cstrong\u003elow to mid single digit range\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\nLow; this is a specific, complex, one-time operational task dictated by the partnership agreement.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\nLow; it is a contractual obligation execution, not a general skill set.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\nYes, the company has made this a near-term priority, indicating internal resources are dedicated to its completion. This dedication was supported by a financial position of \u003cstrong\u003e$46.5 million\u003c\/strong\u003e in cash, cash equivalents and investments as of June 30, 2025, projecting a cash runway into \u003cstrong\u003eQ4 2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\nTemporary; once the transfer was completed on \u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e, this specific capability is no longer a source of advantage, shifting the focus to the subsequent milestone achievement upon relaunch.\n\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eThe successful transfer enables GSK to initiate regulatory interactions with the U.S. Food and Drug Administration in \u003cstrong\u003e2026\u003c\/strong\u003e to discuss the relaunch of BREXAFEMME for VVC and rVVC.\u003c\/li\u003e\n\u003cli\u003eThe company reported Q2 2025 revenue of \u003cstrong\u003e$1.4 million\u003c\/strong\u003e, primarily from license agreement revenue associated with the GSK License Agreement.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the three months ended June 30, 2025, were \u003cstrong\u003e$7.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSCYNEXIS, Inc. (SCYX) - VRIO Analysis: \u003cstrong\u003eResolution of GSK MARIO Study Dispute\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eResolution of GSK MARIO Study Dispute\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The settlement provides an immediate, non-dilutive cash infusion of \u003cstrong\u003e$24.8 million\u003c\/strong\u003e expected in Q4 2025, de-risking near-term operations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; the specific terms of resolving a major dispute with a large partner are unique to this situation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a unique legal and commercial outcome that cannot be replicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, management successfully negotiated and executed the binding memorandum of understanding (MOU).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the benefit is the one-time cash injection and removal of a legal overhang.\u003c\/p\u003e\n\u003cp\u003eFinance: draft the 13-week cash flow projection incorporating the expected \u003cstrong\u003e$24.8 million\u003c\/strong\u003e GSK payment by Friday.\u003c\/p\u003e\n\u003cp\u003eThe latest reported cash position as of September 30, 2025, was \u003cstrong\u003e$37.9 million\u003c\/strong\u003e in cash, cash equivalents and investments. The resolution with GSK adds a one-time payment totaling \u003cstrong\u003e$24.8 million\u003c\/strong\u003e, which is expected in Q4 2025. This influx, combined with existing cash and the elimination of future MARIO study expenditures, extends the company's cash runway to more than two years.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key financial metrics relevant to the cash flow impact:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (as of Sept 30, 2025)\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$37.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnding balance for Q3 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected GSK Payment (One-Time)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected in Q4 2025 from MOU.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Post-Payment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$62.7 million\u003c\/strong\u003e (Approx.)\u003c\/td\u003e\n\u003ctd\u003e$37.9 million + $24.8 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNet loss for the three months ended September 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 License Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$334,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRevenue recognized in Q3 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal R\u0026amp;D ($5.5M) and SG\u0026amp;A ($3.3M).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Level\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eZero\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eConvertible notes repaid at maturity in March 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe expected cash flow update, incorporating the payment received by Friday of the projection period, would reflect the following immediate liquidity enhancement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProjected Cash Balance (Post-GSK Payment): \u003cstrong\u003e$62.7 million\u003c\/strong\u003e (Approximate).\u003c\/li\u003e\n\u003cli\u003eElimination of Future MARIO Study Expenditures: Reduces anticipated operating cash burn.\u003c\/li\u003e\n\u003cli\u003eBREXAFEMME NDA Transfer to GSK: Progressing by the end of 2025.\u003c\/li\u003e\n\u003cli\u003ePotential BREXAFEMME Annual Milestones: Up to approximately \u003cstrong\u003e$146 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDebt-to-Equity Ratio: Extremely low at \u003cstrong\u003e0.05%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516247531669,"sku":"scyx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/scyx-vrio-analysis.png?v=1740213547","url":"https:\/\/dcf-model.com\/fr\/products\/scyx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}